Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co‐administered with metformin
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background: A cohort of patients with type 2 diabetes, prescribed glyburide/metformin tablets, experienced significantly greater improvements in glycaemic control compared to patients receiving glyburide co‐administered with metformin. Aim: To compare the change in A1C for type 2 diabetic patients new to combination therapy with fixed‐dose glyburide/metformin tablets vs. glyburide co‐administered with metformin in a usual‐care setting. Methods: This retrospective cohort study analysed medication usage via an administrative pharmacy claims database and the patients' corresponding laboratory results. Patients were new to antidiabetic combination therapy with glyburide/metformin tablets or glyburide co‐administered with metformin between August 2000 and July 2001 and had A1C measurements at baseline and within 76–194 days of initiating combination therapy. The change from baseline in A1C was analysed using statistical regression to adjust for significant covariates (baseline A1C and dosage). Adherence with therapy was also compared. Results: The cohort consisted of 950 patients who received glyburide/metformin tablets and 471 taking glyburide co‐administered with metformin. Glyburide/metformin patients were younger (mean age = 56 vs. 60 years, p < 0.0001) and received lower doses of each drug than patients taking glyburide co‐administered with metformin (glyburide mean final dose = 6 vs. 10 mg/day, p < 0.0001; metformin = 893 vs. 1297 mg/day, p < 0.0001). The mean decrease from baseline A1C, adjusted for baseline A1C and dosage, of 2.02% for glyburide/metformin tablets was significantly (p < 0.0001) greater than the decrease of 1.49% for glyburide co‐administered with metformin. Glyburide/metformin patients with baseline A1C ≥ 8 experienced a significantly (p < 0.0001) greater decrease in A1C of 2.93% compared to 1.92% for glyburide co‐administered with metformin. For patients with baseline A1C < 8%, the difference between the A1C responses remained significant, even though the reductions in A1C were smaller for both glyburide/metformin tablets and glyburide co‐administered with metformin (0.54% and 0.23%, p = 0.0017). Patients were more adherent with glyburide/metformin tablets (84% vs. 76%, p < 0.0001), though regression analysis indicated that adherence was not a significant predictor of change in A1C. Conclusions: The lower medication doses delivered by glyburide/metformin tablets provided a significantly greater reduction in A1C than did glyburide co‐administered with metformin in patients with type 2 diabetes, especially when baseline A1C ≥ 8%.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
Pharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
Morris, A. D., Boyle, D. I., McMahon, A. D., Greene, S. A., MacDonald, T. M., & Newton, R. W. (1997) · The Lancet · doi:10.1016/s0140-6736(97)06234-x · Cited by 507
Cited by
Fixed-Dose Combinations Improve Medication Compliance: A Meta-Analysis
Bangalore, S., Kamalakkannan, G., Parkar, S., & Messerli, F. H. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.08.033 · Cited by 1,075
Predictors of Adherence With Antihypertensive and Lipid-Lowering Therapy
Chapman, R. H. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.10.1147 · Cited by 506
Cramer, J. A., Benedict, Á., Muszbek, N., Keskinaslan, A., & Khan, Z. M. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01630.x · Cited by 487
A Review of Diabetes Treatment Adherence and the Association with Clinical and Economic Outcomes
Asche, C., LaFleur, J., & Conner, C. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.01.019 · Cited by 420
Hutchins, V., Zhang, B., Fleurence, R. L., Krishnarajah, G., & Graham, J. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.570745 · Cited by 164
“Blonde et al.16 performed a retrospective cohort study analysis using an administrative pharmacy claims database to compare the change in A1c levels and MPR in patients new to combination therapy treated with glyburide/ metformin (FDCT) compared to glyburideþmetformin (LPCT).”
Method
Metadata
- Authors
- Blonde, L., Wogen, J., Kreilick, C., & Seymour, A. A.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2003-11
- Volume
- 5
- Issue
- 6
- Pages
- 424-431
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2114072789
- Cited by
- 73
- References
- 4
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co‐administered with metformin. https://app.cochat.ai/papers/10.1046/j.1463-1326.2003.00297.x
- The paper
- Blonde, L., Wogen, J., Kreilick, C., & Seymour, A. A. (2003). Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co‐administered with metformin. Diabetes, Obesity and Metabolism. https://doi.org/10.1046/j.1463-1326.2003.00297.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.